The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus

• Published in: Reumatismo 2016-12, Vol.68 (3), p.137-143
• Main Authors: Taraborelli, M, Lazzaroni, M G, Martinazzi, N, Fredi, M, Cavazzana, I, Franceschini, F, Tincani, A
• Format: Article
• Language: English
• Subjects: Antibodies, Anticardiolipin - blood; Antibodies, Antiphospholipid - blood; Anticoagulants - blood; antiphospholipid antibodies; antiphospholipid syndrome; Autoimmune diseases; beta 2-Glycoprotein I - blood; Biomarkers - blood; Clinical significance; Cohort Studies; Follow-Up Studies; Humans; Immunoglobulin G - blood; Immunoglobulin M - blood; Immunologic Factors - blood; Lupus; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - immunology; Multivariate analysis; Predictive Value of Tests; Sensitivity and Specificity; Systemic lupus erythematosus; thrombosis; valvulopathy
• ISSN: 0048-7449; 2240-2683
• DOI: 10.4081/reumatismo.2016.891

The objective is to investigate the role of clinically significant antiphospholipid antibodies (aPL) in a cohort of systemic lupus erythematosus (SLE) patients. All SLE patients followed for at least 5 years and with available aPL profile at the beginning of the follow-up in our center were studied. Clinically significant aPL were defined as: positive lupus anticoagulant test, anti-cardiolipin and/or anti- β2Glycoprotein I IgG/IgM >99th percentile on two or more occasions at least 12 weeks apart. Patients with and without clinically significant aPL were compared by univariate (Chi square or Fisher's exact test for categorical variables and Student's t or Mann-Whitney test for continuous variables) and multivariate analysis (logistic regression analysis). P values